- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03563144
QUILT-3.088: NANT Pancreatic Cancer Vaccine
QUILT-3.088 NANT Pancreatic Cancer Vaccine: Phase II Randomized Trial of the NANT Pancreatic Cancer Vaccine vs. Standard-of-Care as First- Line Treatment for Patients With Metastatic Pancreatic Cancer
Study Overview
Status
Conditions
Intervention / Treatment
- Biological: ETBX-021
- Biological: ETBX-051
- Biological: GI-6207
- Biological: GI-6301
- Drug: Bevacizumab
- Drug: Leucovorin
- Drug: 5-Fluorouracil
- Biological: ETBX-011
- Biological: ETBX-061
- Biological: GI-4000
- Drug: Avelumab
- Biological: ALT-803
- Biological: haNK
- Drug: Cyclophosphamide
- Drug: Oxaliplatin
- Drug: Capecitabine
- Drug: Nab-paclitaxel
- Drug: Aldoxorubicin HCl
- Drug: Gemcitabine
Detailed Description
This is a two-cohort, open-label, randomized phase 2 study to evaluate the safety and efficacy (as assessed by PFS) of the NANT Pancreatic Cancer Vaccine regimen (experimental arms) vs SoC therapy (control arms) as first-line treatment for subjects with metastatic pancreatic cancer.
Subjects will be enrolled into two independent cohorts based on ECOG status. Subjects with ECOG 0-1 will be randomized 1:1 to receive the NANT Pancreatic Cancer Vaccine regimen (experimental arm) or gemcitabine in combination with nab-paclitaxel (control arm), while subjects with ECOG 2 will be randomized 1:1 to receive the NANT Pancreatic Cancer Vaccine regimen (experimental arm) or gemcitabine monotherapy (control arm).
The experimental arms will be administered in two phases, an induction and a subsequent maintenance phase. The treatment regimen administered in the experimental arms will be identical for all subjects, independent of ECOG status. Subjects may continue induction treatment for up to 1 year. Those who have a complete response (CR) in the induction phase will enter the maintenance phase of the study. Subjects who experience ongoing stable disease (SD) or an ongoing partial response (PR) after 1 year of induction phase treatment may enter the maintenance phase at the Investigator's discretion. Subjects may remain on the maintenance phase of the study for up to 1 year.
Treatment in the study will be discontinued if the subject experiences confirmed PD or unacceptable toxicity, withdraws consent, or if the Investigator feels it is no longer in the subject's best interest to continue treatment. Subjects receiving treatment in the control arms may cross over to treatment in the induction phase of the experimental arms after experiencing PD. Subjects receiving treatment in the experimental arms with an initial assessment of PD per RECIST 1.1 may, at the discretion of the Investigator, continue to receive study treatment until PD is confirmed. The maximum time on study treatment is 2 years.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
El Segundo, California, United States, 90245
- Chan Soon-Shiong Institute for Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years old.
- Able to understand and provide a signed informed consent that fulfills the relevant IRB or Independent Ethics Committee (IEC) guidelines.
- Histologically-confirmed metastatic pancreatic adenocarcinoma that has not been previously treated with chemotherapy.
- ECOG performance status of 0-2.
- Have at least 1 measurable lesion of ≥ 1.0 cm.
- If available, must be willing to release a recent formalin-fixed, paraffin-embedded (FFPE) tumor biopsy specimen for prospective and exploratory tumor molecular profiling. If an historic specimen is not available, the subject must be willing to undergo a biopsy during the screening period, if considered safe by the Investigator.
- Must be willing to provide blood samples prior to the start of treatment on this study for prospective tumor molecular profiling and exploratory analyses.
- Must be willing to provide a tumor biopsy specimen 8 weeks after the start of treatment for exploratory analyses, if considered safe by the Investigator.
- Ability to attend required study visits and return for adequate follow-up, as required by this protocol.
- Agreement to practice effective contraception for female subjects of child-bearing potential and non-sterile males. Female subjects of child-bearing potential must agree to use effective contraception for up to 1 year after completion of therapy, and non-sterile male subjects must agree to use a condom for up to 4 months after treatment. Effective contraception includes surgical sterilization (eg, vasectomy, tubal ligation), two forms of barrier methods (eg, condom, diaphragm) used with spermicide, intrauterine devices (IUDs), and abstinence.
Exclusion Criteria:
- Serious uncontrolled concomitant disease that would contraindicate the use of the investigational drug used in this study or that would put the subject at high risk for treatment-related complications.
- Systemic autoimmune disease (eg, lupus erythematosus, rheumatoid arthritis, Addison's disease, autoimmune disease associated with lymphoma).
- History of organ transplant requiring immunosuppression.
- History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).
Inadequate organ function, evidenced by the following laboratory results:
- Absolute neutrophil count (ANC) < 1,000 cells/mm^3.
- Platelet count < 75,000 cells/mm^3.
- Total bilirubin greater than the upper limit of normal (ULN; unless the subject has documented Gilbert's syndrome).
- Aspartate aminotransferase (AST [SGOT]) or alanine aminotransferase (ALT [SGPT]) > 2.5 × ULN (> 5 × ULN in subjects with liver metastases).
- Alkaline phosphatase levels (ALP) > 2.5 × ULN (> 5 × ULN in subjects with liver metastases, or >10 × ULN in subjects with bone metastases).
- Serum creatinine > 2.0 mg/dL or 177 μmol/L.
- Serum anion gap > 16 mEq/L or arterial blood with pH < 7.3.
- Medically uncorrectable grade 3 anemia (hemoglobin < 8 g/dL).
- Uncontrolled hypertension (systolic > 160 mm Hg and/or diastolic > 110 mm Hg) or clinically significant (ie, active) cardiovascular disease, cerebrovascular accident/stroke, or myocardial infarction within 6 months prior to first study medication; unstable angina; congestive heart failure of New York Heart Association grade 2 or higher; or serious cardiac arrhythmia requiring medication. Subjects with uncontrolled hypertension should be medically managed on a stable regimen to control hypertension prior to study entry.
- Serious myocardial dysfunction defined by echocardiogram (ECHO) as absolute left ventricular ejection fraction (LVEF) 10% below the institution's lower limit of predicted normal.
- Dyspnea at rest due to complications of advanced malignancy or other disease requiring continuous oxygen therapy.
- Positive results of screening test for human immunodeficiency virus (HIV).
- Current chronic daily treatment (continuous for > 3 months) with systemic corticosteroids (dose equivalent to or greater than 10 mg/day methylprednisolone), excluding inhaled steroids. Short-term steroid use to prevent IV contrast allergic reaction or anaphylaxis in subjects who have known contrast allergies is allowed.
- Known hypersensitivity to any component of the study medication(s).
- Subjects taking any medication(s) (herbal or prescribed) known to have an adverse drug reaction with any of the study medications.
- Concurrent or prior use of a strong cytochrome P450 (CYP)3A4 inhibitor (including ketoconazole, itraconazole, posaconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, and grapefruit products) or strong CYP3A4 inducers (including phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, and St John's Wort) within 14 days before study day 1.
- Concurrent or prior use of a strong CYP2C8 inhibitor (gemfibrozil) or moderate CYP2C8 inducer (rifampin) within 14 days before study day 1.
- History of receiving any investigational treatment for metastatic pancreatic cancer, or participation in an investigational drug study within 30 days prior to screening for this study, except for testosterone-lowering therapy in men with prostate cancer.
- Assessed by the Investigator to be unable or unwilling to comply with the requirements of the protocol.
- Concurrent participation in any interventional clinical trial.
- Pregnant and nursing women.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NANT Pancreatic Cancer Vaccine
in subjects with ECOG=2 or subjects with ECOG=0 or 1 A combination of agents will be administered to subjects in this study: cyclophosphamide, bevacizumab, oxaliplatin, capecitabine, 5-fluorouracil, leucovorin, nab-paclitaxel, aldoxorubicin HCl, avelumab, ALT-803, haNK, GI-4000, GI-6207, GI-6301, ETBX-011, ETBX-021, ETBX-051, ETBX-061. |
Ad5 [E1-, E2b-]-human epidermal growth factor receptor 2 [HER2] vaccine
Ad5 [E1-, E2b-]-Brachyury vaccine
CEA yeast vaccine
Brachyury yeast vaccine
Bevacizumab
L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt
5-fluoro-2,4 (1H,3H)-pyrimidinedione
Ad5 [E1-, E2b-]-CEA
Ad5 [E1-, E2b-]-mucin 1[MUC1]
Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
Avelumab
Recombinant human super agonist interleukin-15 (IL-15) complex
NK-92 [CD16.158V, ER IL-2]
2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Oxaliplatin
Capecitabine
NAB-paclitaxel is a type of chemotherapy called a microtubule inhibitor.
Microtubule inhibitors interfere with a cancer cell's ability to grow and divide.
Albumin-binding prodrug of doxorubicin HCl
|
Active Comparator: Gemcitabine and Nab-paclitaxel
Gemcitabine plus Nab-paclitaxel will be administered to subjects with ECOG=2
|
NAB-paclitaxel is a type of chemotherapy called a microtubule inhibitor.
Microtubule inhibitors interfere with a cancer cell's ability to grow and divide.
Gemcitabine is a type of chemotherapy medication used to interfere with the cancer cells' ability to grow and divide.
|
Active Comparator: Gemcitabine
Gemcitabine will be administered to subjects with ECOG=0 or 1
|
Gemcitabine is a type of chemotherapy medication used to interfere with the cancer cells' ability to grow and divide.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-Free Survival
Time Frame: 12 mths
|
Compare the efficacy of the NANT Pancreatic Cancer Vaccine regimen vs standard-of-care (SoC) therapy as first-line treatment for patients with metastatic pancreatic cancer as assessed by progression-free survival (PFS) using RECIST Version 1.1
|
12 mths
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival
Time Frame: 24 months
|
Overall Survival from first treatment to date of death (any cause)
|
24 months
|
Overall Response Rate
Time Frame: 19 months
|
Overall Response Rate, as determined by the percentage of patients achieving Partial or Complete response per RECIST 1.1 and irRC
|
19 months
|
Duration of Response
Time Frame: 19 months
|
Duration of Response from date of first response to date of disease progression or death (any cause), per RECIST 1.1 and irRC
|
19 months
|
Disease Control Rate
Time Frame: 19 months
|
Disease Control Rate: the number of patients with a CR, PR or SD lasting at least 2 months per RECIST 1.1 and irRC
|
19 months
|
Quality of Life by Patient-Reported Outcomes
Time Frame: 19 months
|
Quality of Life as assessed by Patient Reported Outcomes using the FACT-C questionnaire
|
19 months
|
Progression Free Survival
Time Frame: 12 months
|
Progression Free Survival from baseline to progression per irRC
|
12 months
|
Evaluation of safety as determined by incidence or treatment-emergent adverse events
Time Frame: 19 months
|
Incidence of treatment -emergent adverse events using NCI CTCAE Version 4.03
|
19 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Pancreatic Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Protective Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Phytogenic
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Micronutrients
- Vitamins
- Antidotes
- Vitamin B Complex
- Gemcitabine
- Cyclophosphamide
- Paclitaxel
- Fluorouracil
- Capecitabine
- Oxaliplatin
- Bevacizumab
- Leucovorin
- Avelumab
Other Study ID Numbers
- QUILT-3.088
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Pancreatic Cancer
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Metastatic Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Pancreatic Cancer Non-resectable | Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma... and other conditionsUnited States
-
Orion Biotechnology Polska Sp. z o.o.Not yet recruitingMetastatic Colorectal Cancer | Metastatic Cancer | Metastatic Breast Cancer | Metastatic Urothelial Carcinoma | Metastatic Gastric Cancer | Metastatic Pancreatic Cancer
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI)CompletedMetastatic Colorectal Cancer | Metastatic Pancreatic Cancer | Unresectable Pancreatic CancerUnited States
-
Dana-Farber Cancer InstitutePatient-Centered Outcomes Research Institute; National Cancer Institute (NCI); Alliance for Clinical Trials in OncologyCompletedMetastatic Colorectal Cancer | Metastatic Pancreatic Cancer | Unresectable Pancreatic CancerUnited States
-
University Hospital HeidelbergGerman Cancer Research CenterCompletedColorectal Cancer Metastatic | Pancreatic Cancer MetastaticGermany
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Metastatic Pancreatic Ductal AdenocarcinomaUnited States
-
HonorHealth Research InstituteUniversity of Arizona; Agenus Inc.; Translational Genomics Research InstituteNot yet recruitingPancreatic Cancer Metastatic | Pancreatic Adenocarcinoma MetastaticUnited States
-
Pancreatic Cancer Action NetworkActive, not recruitingMetastatic Pancreatic Adenocarcinoma | Metastatic Pancreatic CancerUnited States
-
Joachim Aerts, MD PhDCompletedMetastatic Pancreatic CancerNetherlands
-
Georgetown UniversityNational Cancer Institute (NCI); Mayo Clinic; Emory University; Indiana University and other collaboratorsTerminatedMetastatic Colorectal Cancer | Pancreatic Adenocarcinoma | Colorectal Adenocarcinoma | Metastatic Pancreatic CancerUnited States
Clinical Trials on ETBX-021
-
NantBioScience, Inc.Unknown
-
Arcturus Therapeutics, Inc.Completed
-
National Cancer Institute (NCI)CompletedHead and Neck Cancer | Head and Neck NeoplasmsUnited States
-
Arcturus Therapeutics, Inc.Terminated
-
Travere Therapeutics, Inc.RecruitingImmunoglobulin A NephropathyUnited States, Hong Kong
-
National Cancer Institute (NCI)CompletedProstatic Neoplasms | Prostatic CancerUnited States
-
Arcturus Therapeutics, Inc.TerminatedCovid19 | Corona Virus Infection | SARS-CoV InfectionUnited States, Singapore
-
ImmunityBio, Inc.Active, not recruiting
-
National Cancer Institute (NCI)CompletedNeoplasms | Breast Cancer | Lung Cancer | Prostate Cancer | Colon CancerUnited States
-
ImmunityBio, Inc.Unknown